01345nam a2200277   4500001000800000005001700008007000300025008004100028040000800069041000800077100003300085245008100118300002300199520045100222650003300673650003200706650003600738650002300774700003100797700002600828700003100854700002500885773010900910942003101019999001701050ESSALUD20260821151611.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aSchett, Georg eAutor954286  aPregnancies in patients with autoimmune disease receiving CAR T-cell therapy  apáginas: 821-824  aAutoimmune diseases preferentially affect women in their childbearing years, potentially interfering with reproduction. Pregnancies in patients with autoimmune diseases are associated with increased maternal and fetal risks. Treatment of autoimmune diseases with autologous CD19–chimeric antigen receptor (CAR) T cells has been shown to lead to sustained drug-free remission, which is expected to be associated with improved pregnancy outcomes.  aENFERMEDAD AUTOINMUNE953665  aCOMPLICACIONES DEL EMBARAZO  aENDOCRINOLOGÍA GENERAL954270  aCÉLULAS T954097  aWirsching, Andreas 954287  aRothe, Tobias 954288  aVisconti, Vanessa  954289  aKramer, Neil 9542900 022717922650dMassachusetts NEJM GroupoNEJM12tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-21zsqb  c22860d22860